This year, Healio covered several studies and updates about treatment options to slow myopia progression, including one about a model developed to predict the onset of myopia.
Here's a list of our top myopia stories from 2024.
SightGlass receives FDA breakthrough designation for spectacle lenses that slow myopia
The FDA has granted breakthrough device designation to SightGlass Vision's diffusion optics technology spectacle lenses, which are designed to slow myopia progression in children.
"Recent studies illustrate that about half of U.S. children are myopic, yet most are not receiving treatments proven to slow myopia progression," Andrew Sedgwick, SightGlass Vision's CEO, said in a company press release. "We are enthusiastic about more closely collaborating with the FDA as we pursue U.S. market clearance." Read more.
Study of atropine-based myopia treatment fails to meet primary efficacy endpoint
Eyenovia's phase 3 CHAPERONE study evaluating low-dose atropine delivered via the company's Optejet dispenser is not meeting its primary endpoint of a less than 0.50 D progression in visual acuity over 3 years, according to a press release.
"We are disappointed that the [Data Review Committee (DRC)] determined that the CHAPERONE study does not appear to be meeting its primary efficacy endpoint," Michael Rowe, Eyenovia's CEO, said in the release. "We plan to terminate the study, review the data more thoroughly and evaluate next steps." Read more.
Control myopia in children to prevent retinal problems later in life
Most parents are unaware of the complications of high myopia as well as the potential to control it in children, Janelle Davison, OD, said at Vision Expo East.
"Every 1 D increase in myopia increases the risk of myopic macular degeneration by 67% and retinal detachment by 30%," Davison said, citing a study by Bullimore and colleagues published in Optometry & Vision Science. Read more.
Naked-eye 3-D vision training safe, effective in treating myopia in children
Naked-eye 3-dimensional vision training was safe and controlled progression of axial length and spherical equivalent refraction in children with myopia, according to a study conducted in China and published in JAMA Pediatrics.
"To prevent the occurrence and progression of myopia in children, many myopia intervention methods have been developed, including orthokeratology, soft contact lenses and low-concentration atropine eye drops," Rui Xie, MM, of Sun Yat-sen University in China, and colleagues wrote. "For interventions used in children and adolescents, safety is a key concern for clinicians and parents." Read more.
Model may help predict onset of myopia in children up to age 14 years
Refractive error, age, sex and race/ethnicity can be predictive factors in determining the probability of myopia onset in prepubescent children, according to a study published in Optometry and Vision Science.
"A predictive model would be useful for sample size planning in myopia prevention clinical trials, providing estimates of the likelihood of conversion from emmetropia to myopia, given different sample configurations of age, sex, race/ethnicity, baseline refractive error or other significant covariates," Donald O. Mutti, OD, PhD, FAAO, the E.F. Wildermuth Foundation Professor in Optometry at The Ohio State University College of Optometry, and colleagues wrote. "A predictive model would help the clinician advise an individual child and their family on the probability of future refractive error." Read more.
Topline results show MyopiaX light stimulation safe, tolerable in children
Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.
"The 6-month outcomes represent a significant step in the clinical development of MyopiaX," Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press release. "The results are an important addition to the existing evidence supporting the mechanism of action of MyopiaX light stimulation." Read more.